Impact (REF3a/b)

Impact template (REF3a)

Download template (73K)

All impact case studies

Download all case studies (2.9MB)

Individual case studies

Curing chronic granulomatous disease in children through early bone marrow transplant (358K)

Diagnostic test for the rare muscular disorder limb-girdle muscular dystrophy type 2A (178K)

How better risk stratification for lung transplant has benefitted cystic fibrosis patients (110K)

Identification of a chromosomal abnormality now used to stratify treatment in children with neuroblastoma. (188K)

Improving the quality and length of the lives of Duchenne muscular dystrophy patients through the application of multidisciplinary care (232K)

Increased range and adoption of evidence-based treatments for refractory moderate-to-severe atopic eczema (275K)

Innovations in the treatment of chronic myeloid leukemia have almost doubled 5-year survival rates. (228K)

Optimising the treatment of childhood cancer through therapeutic drug monitoring (195K)

pGALS: a novel and simple approach for musculoskeletal examination of children (166K)

Reducing the toxicity of pemetrexed treatment in malignant pleural mesothelioma. (185K)

Simple, non-invasive, diagnosis of liver fibrosis severity in Non-alcoholic Fatty Liver Disease (NAFLD) (218K)

The development of a novel class of anticancer drugs, PARP inhibitors, has attracted multi-million dollar investments in clinical trials by nine pharmaceutical companies (141K)

Towards prevention of mitochondrial diseases: changing government policy and influencing public debate. (157K)

Uncovering the genetic basis of atypical haemolytic uraemic syndrome leads to improved treatment. (158K)

Use of non-invasive ventilation to improve survival and quality of life in patients with motor neuron disease (203K)

Using genetics to inform prescription of warfarin and thereby enhance patient safety (162K)